Oppenheimer analyst Leland Gershell downgraded Essa Pharma (EPIX) to Perform from Outperform without a price target The company announced that it will discontinue all masofaniten development following a prespecified futility analysis that showed that this candidate failed to meet the target efficacy profile in the Phase 2 enzalutamide combo study, the analyst tells investors in a research note. The firm awaits details as Essa moves to a strategic process in which it will explore options that can maximize shareholder value.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPIX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue